Navigation Links
BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of First Quarter 2013 Financials
Date:5/9/2013

RALEIGH, N.C., May 9, 2013 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that it has filed its Quarterly Report on Form 10-Q for the quarter ended March 31, 2013, with the U.S. Securities and Exchange Commission and, in connection therewith, is providing a review of BDSI's recent achievements and an update on business operations and upcoming milestones for 2013.

(Logo: http://photos.prnewswire.com/prnh/20110217/CL49801LOGO )

Continued progress was made in the development of BDSI's two buprenorphine-containing products with the completion in January 2013 of the safety study for BUNAVAIL for the treatment of opioid dependence.  The study, which included 249 patients who were switched from Suboxone to BUNAVAIL, demonstrated the ease of use and tolerability of BUNAVAIL.

In addition, recruitment continued toward a late 2013 or early 2014 completion of the two ongoing Phase 3 studies for BEMA Buprenorphine for the treatment of chronic pain, which are being conducted in conjunction with BDSI's partner, Endo Health Solutions.

At March 31, 2013, BDSI had $49.7 million in cash compared to $63.2 million at December 31, 2012 and $32.1 million at March 31, 2012.  Cash used in operations for the first quarter of 2013 totaled $13.5 million.  Research and development costs were $12.0 million in the first quarter of 2013, compared to a corresponding $4.7 million in the first quarter of 2012.  The current quarter increase over the prior year first quarter is due primarily to additional research and development costs associated with the concomitant running of the BUNAVAIL and BEMA Buprenorphine late stage development programs.  Also contributing to the increase was the recording in March 2013 of $2.1 million of in-proce
'/>"/>

SOURCE BioDelivery Sciences International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of its Second Quarter 2012 Financials
2. BioDelivery Sciences Receives Patent Allowance Triggering $15 Million Milestone Payment from Endo Pharmaceuticals
3. Neurocrine Biosciences To Present At The Bank of America Merrill Lynch 2013 Health Care Conference
4. R. Graham Cooks Wins Dreyfus Prize in the Chemical Sciences; Purdue Chemist Honored for Advances in Chemical Instrumentation
5. BioConvergence® Celebrates Seventh Anniversary as a Life Sciences Contract Service Provider
6. Best Practices for Conducting Extractable and Leachable Studies, new life sciences webinar hosted by Xtalks
7. Tunnell Consulting Names John S. Ross as Principal, Life Sciences
8. Provitro Biosciences Awarded First-Ever U.S. Patent For Large-Scale Production Of Bamboo Plants
9. Partnership between EBSCO Publishing and BioOne Online Journals Adds Scholarly Biological, Ecological and Environment Sciences Articles to EBSCO Discovery Serviceā„¢
10. MedeAnalytics Ken Perez Predicts Rapid Growth of Healthcare Data Analytics Market at Conference on Data Analytics in Life Sciences, Healthcare and Biotech Companies
11. Regado Biosciences, Inc. Files Registration Statement for Proposed Initial Public Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)...  ( www.competitivehealth.com ) — Competitive Health is pleased ... and advocacy service, has signed an agreement to become ... health services marketplace. 63% of Americans have ... expected to pay. As part of an ongoing effort ... is pleased to offer medical bill review and negotiation ...
(Date:12/22/2014)... Fertility Associates of Memphis has announced a ... a network of more than 20 contributing fertility ... fast access to a national pool of frozen ... Associates of Memphis is the only fertility clinic in ... Dr. William Kutteh , director of Fertility Associates ...
(Date:12/19/2014)... December 19, 2014 BioPlus Specialty ... pharmacies, announces the promotion of Nick Maroulis, Pharm.D. to ... Pharmacy Services. , In this position, Dr. Maroulis ... also managing the directors of our multi-site pharmacies as ... since 1997 and during that time he has served ...
(Date:12/19/2014)... , Dec. 19, 2014 Bina Technologies, Inc. ... announced today that they have been acquired by Roche ... is a privately held company that provides a big ... generation sequencing (NGS) data for the academic and translational ... Sequencing Unit, and will continue to focus on development ...
Breaking Biology Technology:WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 3BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2Bina Technologies is acquired by Roche. 2Bina Technologies is acquired by Roche. 3
... Corporation (NYSE:,DHR) announced that President and Chief Executive ... the J.P. Morgan Healthcare Conference in,San Francisco on ... audio will be,simultaneously webcast on http://www.danaher.com . ... for one week., Danaher Corporation is a ...
... China Technology,Development Group Corporation (Nasdaq: CTDC; "the Company" ... products and solutions focusing on,solar energy business in ... ceremony to showcase the first SnO2 production line ... 2007., Accompanied by Mr. Alan Li, our ...
... 3 Neogen Corporation,(Nasdaq: NEOG ) announced today ... 2008, which ended Nov. 30, increased 34% from the ... net income in the,quarter rose to $0.22 per share, ... income of $3,254,000 set another quarterly,record for the 25-year-old ...
Cached Biology Technology:CTDC Holds a Ribbon Cutting Ceremony to Showcase First SnO2 Production Line 2CTDC Holds a Ribbon Cutting Ceremony to Showcase First SnO2 Production Line 3Neogen Reports 34% Increase in Net Income, 23% Increase in Revenues 2Neogen Reports 34% Increase in Net Income, 23% Increase in Revenues 3Neogen Reports 34% Increase in Net Income, 23% Increase in Revenues 4Neogen Reports 34% Increase in Net Income, 23% Increase in Revenues 5
(Date:12/5/2014)... Dec. 4, 2014  Tute Genomics, a leader in ... in Series A1 funding led by UK-based Eurovestech. Peak ... in the investment round. "We are at ... adopts next-generation sequencing and seeks new approaches for the ... Robison , MD MBA, and CEO of Tute Genomics. ...
(Date:11/21/2014)... Nov. 19, 2014  Earlier this year Donald ... College, and one of the most prolific inventors in ... are transmitted from Smartphones to third party agencies. Spector ... has one of the earliest known patents in this ... in the military, child care, elder care and hospital ...
(Date:11/18/2014)...   News Highlights: ... The Partners Data Lake, an agile data and ... will allow researcher and clinicians to explore and ... lives of patients , The Partners Data ... the Partners system, breaking down physical barriers for ...
Breaking Biology News(10 mins):Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5
... the world,s two best-loved flavours and demand for it is ... global food industry could be more secure, thanks to research ... a compound that comes from the vanilla bean, the ,fruit, ... climbing vine originally cultivated by ancient Central American civilisations such ...
... An experimental drug that blocks two points of a ... ovarian cancer cells and significantly increases survival in an ... Comprehensive Cancer Center has found. The drug, called ... have become resistant to the conventional treatment with platinum ...
... gene defect in Wiskott-Aldrich syndrome, an inherited immune deficiency disorder, researchers ... in a 13-year-old boy with the disease. The study, at The ... elements of the body,s immune system, may be used to treat ... ...
Cached Biology News:Preserving a world favorite flavour 2Experimental drug inhibits cell signaling pathway and slows ovarian cancer growth 2Novel therapy improves immune function in teen with rare disease 2
Kinase Buffer can be used to assay protein kinase activity...
Goat polyclonal to SPFH2 ( Abpromise for all tested applications). Antigen: Synthetic peptide: EDEPLETATKEN, corresponding to C terminal amino acids 328-339 of Human SPFH2 Entrez Gene ID: 11...
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
alpha/beta-Tubulin Antibody Ship: Hot Store: -20 C...
Biology Products: